DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Real-time Boerse Frankfurt Warrants 13:07:12 19/06/2024 BST | ||
| 33.85 EUR | +0.15% |
|
| Current month | +0.99% | ||
| 1 month | -1.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 33.85 | +0.15% |
| 18/06/24 | 33.8 | -0.18% |
| 17/06/24 | 33.86 | -0.94% |
| 14/06/24 | 34.18 | +0.12% |
| 13/06/24 | 34.14 | -0.03% |
Real-time Boerse Frankfurt Warrants
Last update June 19, 2024 at 01:07 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM8MBZ |
| ISIN | DE000VM8MBZ1 |
| Date issued | 17/01/2024 |
| Maturity | 20/12/2024 (184 Days) |
| Parity | 1 : 1 |
| Emission price | 34.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 35.48 € |
|---|---|
| Lowest since issue | 33.18 € |
| Spread | 0.35 € |
| Spread % | 1.02% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.81
USD
Average target price
53.19
USD
Spread / Average Target
+30.35%
- Stock Market
- Certificates
- Certificat